Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | JAK3 |
Variant | G589D |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | JAK3 G589D lies within protein kinase domain 1 of the Jak3 protein (UniProt.org). G589D has not been biochemically characterized, but results in transformation of cells in culture (PMID: 28284718), and therefore, is predicted to lead to a gain of Jak3 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
JAK3 mutant JAK3 act mut JAK3 G589D |
Transcript | NM_000215.4 |
gDNA | chr19:g.17837149C>T |
cDNA | c.1766G>A |
Protein | p.G589D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000215.3 | chr19:g.17837149C>T | c.1766G>A | p.G589D | RefSeq | GRCh38/hg38 |
XM_011527991.3 | chr19:g.17837149C>T | c.1766G>A | p.G589D | RefSeq | GRCh38/hg38 |
XM_005259896 | chr19:g.17837995_17837996delCCinsGT | c.1766_1767delGGinsAC | p.G589D | RefSeq | GRCh38/hg38 |
XM_011527991 | chr19:g.17837995_17837996delCCinsGT | c.1766_1767delGGinsAC | p.G589D | RefSeq | GRCh38/hg38 |
NM_000215 | chr19:g.17837149C>T | c.1766G>A | p.G589D | RefSeq | GRCh38/hg38 |
NM_000215.4 | chr19:g.17837149C>T | c.1766G>A | p.G589D | RefSeq | GRCh38/hg38 |
XM_011527990.1 | chr19:g.17837995_17837996delGGinsAC | c.1766_1767delGGinsAC | p.G589D | RefSeq | GRCh38/hg38 |
XM_011527990 | chr19:g.17837995_17837996delCCinsGT | c.1766_1767delGGinsAC | p.G589D | RefSeq | GRCh38/hg38 |
XM_005259896.3 | chr19:g.17837995_17837996delGGinsAC | c.1766_1767delGGinsAC | p.G589D | RefSeq | GRCh38/hg38 |
XM_011527991.2 | chr19:g.17837995_17837996delGGinsAC | c.1766_1767delGGinsAC | p.G589D | RefSeq | GRCh38/hg38 |
XM_047438786.1 | chr19:g.17837149C>T | c.1766G>A | p.G589D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 G589D | hematologic cancer | sensitive | Tofacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib, CP-690,550) decreased cell viability in transformed mouse Ba/F3 cells expressing Jak3 G589D (PMID: 28284718). | 28284718 |